anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Mucus hypersecretion resulting from excessive proliferation and metaplasia of goblet cells in the airways is the pathological foundation for Chronic obstructive pulmonary disease (COPD). Clinical trials have confirmed the clinical efficacy of pulsed electric field ablation (PFA) for COPD, but its underlying mechanisms is poorly understood. Cellular and animal models of COPD (rich in goblet cells) were established in this study to detect goblet cells' sensitivity to PFA. Schwan's equation was adopted to calculate the cells' transmembrane potential and the electroporation areas in the cell membrane. We found that goblet cells are more sensitive to low-intensity PFA (250 V/cm-500 V/cm) than BEAS-2B cells. It is attributed to the larger size of goblet cells, which allows a stronger transmembrane potential formation under the same electric field strength. Additionally, the transmembrane potential of larger-sized cells can reach the cell membrane electroporation threshold in more areas. Trypan blue staining confirmed that the cells underwent IRE rate was higher in goblet cells than in BEAS-2B cells. Animal experiments also confirmed that the airway epithelium of COPD is more sensitive to PFA. We conclude that lower-intensity PFA can selectively kill goblet cells in the COPD airway epithelium, ultimately achieving the therapeutic effect of treating COPD.
Environmentally induced dry eye is a condition which occurs in otherwise asymptomatic individuals in certain situations, for example with the use of computers, in overheated or air conditioned workplaces and in conditions of low humidity. The most common ocular complaints associated with these environments are burning, dryness, stinging, and grittiness. Although the exact cause of these symptoms is unknown, it is thought that increased tear evaporation rate due to low humidity plays a vital role. The changes in tear film physiology, which occurs in these environments, have traditionally been dealt with by the use of eye drops (particularly the highly viscous variety), which have been shown to be an effective therapeutic option in the treatment of environmental dry eye disease. Previous studies of the use of eye-drops of various formulations has shown improvements in tear physiology in mild to moderate dry eye patients with their use in both acute and chronic application protocols. In this study, an attempt was made to relate the effects on tear physiology induced by variations in environmental conditions to the beneficial effect produced by the use of eye-drops.
Post-infectious myalgic encephalomyelitis/chronic fatigue syndrome (PI-ME/CFS) is a disabling disorder, yet the clinical phenotype is poorly defined, the pathophysiology is unknown, and no disease-modifying treatments are available. We used rigorous criteria to recruit PI-ME/CFS participants with matched controls to conduct deep phenotyping. Among the many physical and cognitive complaints, one defining feature of PI-ME/CFS was an alteration of effort preference, rather than physical or central fatigue, due to dysfunction of integrative brain regions potentially associated with central catechol pathway dysregulation, with consequences on autonomic functioning and physical conditioning. Immune profiling suggested chronic antigenic stimulation with increase in naïve and decrease in switched memory B-cells. Alterations in gene expression profiles of peripheral blood mononuclear cells and metabolic pathways were consistent with cellular phenotypic studies and demonstrated differences according to sex. Together these clinical abnormalities and biomarker differences provide unique insight into the underlying pathophysiology of PI-ME/CFS, which may guide future intervention.
The invention is directed to a clinical research data management system and method for a plurality of disparate users. The system includes a presentation creation mechanism operable to provide users with data from a database, an application control and navigation mechanism operable to service user requests and a data access mechanism operable to access information that resides in the database. The database is operable to store user data and study data. The study data includes candidate data, specimen data, event data and at least one dataset. The dataset is defined using metadata. The database is operable to store at least one roll associated with each user. User access to study data, candidate data, specimen data, event data and/or data sets is individually limited based on the at least one role associated with each user.
Prednisone Tablets USP are available for oral administration containing either 1 mg, 2.5 mg, 5 mg, 10 mg, 20 mg or 50 mg of prednisone USP. Each tablet contains the following inactive ingredients: lactose monohydrate, magnesium stearate, microcrystalline cellulose, pregelatinized starch, sodium starch glycolate and stearic acid (1 mg, 2.5 mg, and 5 mg only).

Prednisone Oral Solution USP is formulated for oral administration containing 5 mg per 5 mL of prednisone USP and alcohol 5%. The oral solution contains the following inactive ingredients: anhydrous citric acid, edetate disodium, fructose, hydrochloric acid, maltol, peppermint oil, polysorbate 80, propylene glycol, saccharin sodium, sodium benzoate, vanilla flavor and purified water.

Prednisone Intensol™ Oral Solution (Concentrate) is formulated for oral administration containing 5 mg per mL of prednisone USP and alcohol 30%. In addition, the oral solution contains the following inactive ingredients: anhydrous citric acid, poloxamer 188, propylene glycol and purified water. 

Prednisone tablets contain prednisone which is a glucocorticoid. Glucocorticoids are adrenocortical steroids, both naturally occurring and synthetic, which are readily absorbed from the gastrointestinal tract. The chemical name for prednisone is 17,21-dihydroxypregna-1,4-dienne-3,11,20-trione. The structural formula is represented below:

C 21H 26O 5 M.W. 358.44 

Prednisone is a white to partially white, crystalline powder. It is very slightly soluble in water; slightly soluble in alcohol, chloroform, dioxane, and methanol.
Will be offered an initial one week (5 days for 3 hours each) supervised exercise prehabilitation program including a two hour group-based prehabilitation class at Penn State Rehabilitation Hospital, Hummelstown. The following weeks till surgery the learned exercise program should be done home-based for 5 times a week. A weekly phone call during this period will help to support and adapt the exercise program.
For 7 days, the participants will consume high protein beverage breakfast meals each morning. These meals will consist of shakes and will be 350 kcal. The macronutrient composition of these meals will contain 30 g of dietary protein, 35g CHO, and 10g fat. The HP-S and HP-B meals will be matched for energy density, sugar content, macronutrient content and types of proteins.
A human gamma herpesviris genome known as Kaposi sarcoma associated herpesvirus (KSHV) or human herpesvirus 8 (HHV-8) is present in virtually all AIDS and non-AIDS Kaposi's sarcoma (KS) lesions, as well as in body cavity based lymphomas (BCBL), Multiple myeloma, and in multicentric Casdeman's disease. Isolation and DNA sequencing of a 17-kb segment encompassing a HHV-8 divergent locus (DL-B) between ORF11 and ORF17 revealed the presence of nine viral ORFs with gene products related to cellular proteins. These include the complete thymidylate synthase (TS) gene and a dihydrofolate reductase (DHFR) gene, four cytokine genes (vIL6, vMIP-1A, vMIP-1B and BCK) that have not previously been found to be encoded by a virus, and a Bcl2 homologue. This region in HHV-8 also contains the T1.1 abundant lytic cycle nuclear RNA gene and encompasses two genes (or exons) encoding proteins with C4HC3 zinc finger domains of the PHD/LAP subtype. The latter are related to the spliced immediatelady IE1 protein of the bovine gamma-2 class herpesvirus BHV-4 and a similar motif found in HVS ORF12. Transcripts form the IE-1A, IE-1B, DHFR, and MIP-1B genes were all detected by Northern blot hybridization analysis in a BCBL cell line at 12-h after induction with butyrate, but were not present before induction, indicating that these are all primarily lytic cycle genes.
Same as above, both positive are considered high-risk group.Part of high-risk nodules (5-10mm) will be reviewed every 3 months for the above two examinations, which is expected to be reviewed 6 times in total. Biopsy or surgical resection of high-risk nodules over 10mm will be performed after evaluation by the expert group and the patient's knowledge, and histopathological diagnosis will be made and compared with ctDNA methylation results. To analyze the sensitivity and specificity of ctDNA methylation markers in lung cancer.
Intervention: The Optiflow(R) device supplies oxygen in controlled concentrations and at high flow (from 10 to 70 liters/min) through special nasal cannulae. The device also humidifies the gases mixtures up to 100% relative humidity.
Mutations of human TBC1D24 are associated with deafness, epilepsy, or DOORS syndrome (deafness, onychodystrophy, osteodystrophy, cognitive disability, and seizures). The causal relationships between TBC1D24 variants and the different clinical phenotypes are not understood. Our hypothesis is that phenotypic heterogeneity of missense mutations of TBC1D24 results, in part, from perturbed binding of different protein partners. To discover novel protein partners of TBC1D24, we conducted yeast two-hybrid (Y2H) screen using mouse full-length TBC1D24 as bait. Kidney and brain protein (KIBRA), a scaffold protein encoded by Wwc1, was identified as a partner of TBC1D24. KIBRA functions in the Hippo signaling pathway and is important for human cognition and memory. The TBC1D24 TLDc domain binds to KIBRA full-length and to its C2 domain, confirmed by Y2H assays. No interaction was detected with Y2H assays between the KIBRA C2 domain and TLDc domains of NCOA7, MEAK7, and OXR1. Moreover, the C2 domains of other WWC family proteins do not interact with the TLDc domain of TBC1D24, demonstrating specificity. The mRNAs encoding TBC1D24 and KIBRA proteins in mouse are coexpressed at least in a subset of hippocampal cells indicating availability to interact in vivo. As two epilepsy-associated recessive variants (Gly511Arg and Ala515Val) in the TLDc domain of human TBC1D24 disrupt the interaction with the human KIBRA C2 domain, this study reveals a pathogenic mechanism of TBC1D24-associated epilepsy, linking the TBC1D24 and KIBRA pathways. The interaction of TBC1D24-KIBRA is physiologically meaningful and necessary to reduce the risk of epilepsy.
In this cross-sectional study, patients with various stages of 1st carpometacarpal (CMC) joint osteoarthritis (OA) were assessed using standard radiographs based on the Modified Eaton Litter classification. Postmenopausal women with clinical and/or radiological evidence of 1st CMC OA will be included (Group 1). In the healthy control group, subjects will be matched based on age and hand dominance (Group 2). Demographic information including age, sex, height, weight, body mass index (BMI, kg/m²), dominant hand, and symptom duration (in months) will recorded. Pain levels will be assessed using the Visual Analogue Scale (VAS).The thickness of the thenar eminence muscles (longitudinal thickness of the first dorsal interosseous muscle (FDI), abductor pollicis brevis (APB), and opponens pollicis (OPP)) was measured using musculoskeletal ultrasound. Muscle strength in both hands will be evaluated using grip strength measured with a dynamometer . Pressure pain threshold (PPT) for painful and non-painful finger joints will be assessed using a hand-held algometer
The purpose of this 4-week randomized study is to evaluate the effect of personalized implementation intentions plus an email campaign, with and without email-based coaching (eCoaching), on engagement in a new weekday outdoor walking (WOW) routine and average daily step count. Approximately 150 participants will be recruited via paid ads on Facebook and Instagram. Participants will be randomized (1:1:1) to a control group, an intervention group without eCoaching, and an intervention group with eCoaching. The control group will be told that they can work a WOW routine on their own, with the opportunity to take part in the intervention after completing the 4-week follow-up assessment. Both intervention groups will complete an activity that will guide the creation of a habitual instigation implementation intention (e.g., When I finish eating lunch at work, then I will put on my walking shoes and go outside) and receive a 2-week long personalized email campaign. The primary outcome of interest is change in average daily step count from the month prior to the month after baseline assessment, as compared across the three groups. It is hypothesized that the intervention groups will result in a statistically significant increase in daily step count, as compared to the control group. Secondary outcomes include instigation habit strength (via Self-Report Behavioral Automaticity Index) at one-month follow-up and change in self-reported sleep quality (via the Single Items Sleep Quality Scale) and general self-efficacy (via General Self-Efficacy Scale) from baseline to follow-up.
<P>PROBLEM TO BE SOLVED: To improve convenience in issuing an examination order when additional examination is necessary.  <P>SOLUTION: A report generation server 70 generates image reading report information including examination order information on the basis of an instruction signal from a PC terminal 60 for an image reading doctor. Then, the report generation server 70 makes accessory information accessory to the generated image reading report information, and generates an HL7 report object, and transmits it to an electronic medical record server 10. Then, the electronic medical record server 10 extracts examination order information from the image reading report information included in the HL7 report object, and generates an examination order message on the basis of the examination order information. Then, the electronic medical record server 10 transmits the examination order message to the information management device (EIS30 or PIS80) of an examination department system.  <P>COPYRIGHT: (C)2009,JPO&INPIT
This is an open-labeled, randomized clinical trial. After ICFs are signed, patients' medical history will be gained for checking if they are eligible for this study or not. And then, on Day -1, eligible ones will randomly be divide into two separate group: NALDEBAIN or MORPHINE. Group NALDEBAIN will receive Nadebain by gluteus maximus injection between 12 and 24 hours prior to surgery for postoperative pain relief. Group MORPHINE will receive morphine as needed after surgery. All necessary data will be gain form EMR or patient dairies.
Methylene blue can cause fetal harm when administered to a pregnant woman. An association exists between the use of methylene blue in amniocentesis and atresia of the ileum and jejunum, ileal occlusions, and other adverse effects in the neonate. (2, 3)

Methylene blue is contraindicated in women who are or may become pregnant. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus.

Intraspinal and subcutaneous injections are contraindicated.

Methylene blue is contraindicated in patients with a known hypersensitivity to the drug.
PURPOSE:To obtain a colloid-chemically and biochemically stable fat emulsion capable of including and holding fat-soluble substances in large quantities by adding a polysaccharide deriv. contg. fatty acid or cholesterol substd. in a specified ratio. CONSTITUTION:Hydroxyl groups in polysaccharide such as pullulan, amylopectin, amylose, dextrin, cyclodextrin or dextran are substd. for fatty acid or cholesterol by 0.5-5 groups per 100 saccharide units to obtain a polysaccharide deriv. In the case of <0.5 degree of substitution, a stable fat emulsion is not obtd. In the case of >5 degree of substitution, it is difficult to synthesize the deriv. A fat emulsion is prepd. by adding the polysaccharide deriv. to oil such as fish oil or vegetable oil and water. The emulsification or uniform dispersion of a fat-soluble substance in the water is facilitated and especially fat-soluble chemicals can be solubilized in large quantities. The fat emulsion is widely applicable to food chemistry and other industry.
Schistosoma reflexum (SR) is a lethal congenital syndrome characterized by U-shaped dorsal retroflexion of the spine and exposure of abdominal viscera. SR is usually associated with severe dystocia. The syndrome is thought to be inherited as a Mendelian trait. We collected a series of 23 SR-affected calves from four breeds (20 Holstein, one Red Danish, one Limousin, one Romagnola) and performed whole-genome sequencing (WGS). WGS was performed on 51 cattle, including 14 cases with parents (trio-based; Group 1) and nine single cases (solo-based; Group 2). Sequencing-based genome-wide association studies with 20 Holstein cases and 154 controls showed no association (above Bonferroni threshold; P-value<3 ×10-09). Assuming a monogenic recessive inheritance, no region of shared homozygosity was observed, suggesting heterogeneity. Alternatively, the presence of possible dominant acting de novo mutations were assessed. In Group 1, heterozygous private variants, absent in both parents, were found in seven cases. These involved the ACTL6A, FLNA, GLG1, IQSEC2, MAST3, MBTPS2, and MLLT1 genes. In addition, heterozygous private variants affecting the genes DYNC1LI1, PPP2R2B, SCAF8, SUGP1, and UBP1 were identified in five cases from Group 2. The detected frameshift and missense variants are predicted to cause haploinsufficiency. Each of these 12 affected genes belong to the class of haploinsufficient loss-of-function genes or are involved in embryonic and pre-weaning lethality or are known to be associated with severe malformation syndromes in humans and/or mice. This study presents for the first time a detailed genomic evaluation of bovine SR, suggesting that independent de novo mutations may explain the sporadic occurrence of SR in cattle.
The kit for locating a vein is configured for use in inserting an intravenous (IV) catheter into a targeted vein of a patient. The kit for locating a vein is a transparent structure. The kit for locating a vein: a) removably attaches to the skin of the patient; b) numbs the skin of the patient; c) generates a vasomotor response; d) provides the ability to insert the IV catheter into the targeted vein while the kit for locating a vein remains attached to the patient; and, e) forms a dressing that captures bodily fluids. The kit for locating a vein comprises a parchment sheeting, a working media, a transparent pocket, and a plurality of apertures. The parchment sheeting, the working media, and the transparent pocket form a transparent composite textile structure. The plurality of apertures are apertures that are formed through the composite textile structure.
PURPOSE:The titled composition comprising polyvinyl alcohol, a methoxyethylene-maleic anhydride copolymer, an alkylene glycol, and the rest of water, curing itself to form a film when applied to the skin. CONSTITUTION:An external preparation composition useful preferably as a base for external use of slightly soluble drug such as steroids, containing 0.5-10wt% polyvinyl alcohol, 0.5-5wt% methoxyethylene-maleic anhydride, 20-80wt% alkylene glycol, and the rest of water. The polyvinyl alcohol has preferably 300-2,400 average polymerization degree. This composition is a semisolid having proper hardness, and it is applied in the same way as a conventional ointment or cream. The film of it is stuck fast to the skin for 12-24hr, has neither unpleasant feeling nor feeling of physical disorder, and has no difficulty in life. The film after use can be easily removed with fingers or by washing with water.
Chronic graft-versus-host disease (cGVHD) negatively impacts long-term survival and quality of life (QOL) after allogeneic hematopoietic cell transplantation. Corticosteroids are the first-line treatment for cGVHD, but approximately 30% to 70% of patients develop steroid-refractory cGVHD (SR-cGVHD), which has an extremely poor prognosis. The pathophysiology of cGVHD is more complicated than acute GVHD, but recent advances using murine models in conjunction with human studies indicate three major phases: 1) acute inflammation, 2) chronic inflammation with loss of immune tolerance, and 3) disrupted target organ homeostasis and fibrosis. Strategies that help prevent cGVHD include optimal donor selection and choice of conditioning regimen as well as pharmacologic and graft manipulation strategies. The key cellular mediators of SR-cGVHD are T cells, B cells, antigen-presenting cells, and fibroblasts. T cells and B cells are now targetable with the inhibitors ibrutinib and ruxolitinib, respectively. Recently, promising results have been obtained by modulating pathologic T cell responses with Rock2 inhibitors and targeting fibrosis with CSF-1R inhibitors. To optimize the use of these medications, a better understanding of the biological and target organ-specific mechanisms of cGVHD is needed. Here we review recent advances in cGVHD pathogenesis and discuss how best to implement recently approved biology-driven treatments for cGVHD.
Immediate Endocrine Therapy. Orchiectomy or LHRH Agonist Therapy plus (initially) Antiandrogen Therapy. Buserelin (BSRL); Cyproterone acetate (Androcur) (CPTR), Cyproterone acetate (Androcur)(NSC-81430). Treatment initiated within 1 month of randomization.
Patients will be given earphones to hear a hypnotic script that was recorded by Dr. Zahi Arnon, a psychologist specializing in hypnosis after observing about ten bone marrow (BM) examinations at the hematology institute. The length of the recording is about 7 minutes.
Normal lifestyle. Subjects will undergo a muscle and fat biopsy at the start of the 4 w period and after. An oral glucose test at the start and after completion of the 4 week period. Physical activity and glucose will be monitored during the study period.
Novel topical or transdermal nanoformulations of diclofenac are provided. The preparation is in the form of micelle solution. The micellar solution comprises an alkali metal salt of diclofenac, a solvent, a mixture of surfactants, and an aqueous continuous external phase at a concentration of about 2% to about 5.5% (weight/weight). The micellar solution may optionally further comprise a penetration enhancer. The micellar solution may be gelled with a suitable gelling agent. The disclosed compositions are useful for treating joint pain, osteoarthritis, muscle pain, back pain, and/or inflammation.
An osmotic system for delivering a beneficial agent is disclosed. The system comprises a wall surrounding a compartment and has a passageway through the wall for delivering agent from the compartment. The wall is formed of a material permeable to the passage of an external fluid and impermeable to the passage of agent. The compartment contains an agent that is soluble in the fluid and exhibits an osmotic pressure gradient across the wall against the fluid, or the compartment contains an agent that has limited solubility in the fluid and exhibits a limited osmotic pressure gradient across the wall against the fluid. The compartment also contains means for increasing the amount of agent delivered from the system. The means comprises a film surrounding an osmagent with the film formed of a material permeable to fluid, impermeable to osmagent and movable from an initial to an expanded state. In operation, agent is delivered from the system through the passageway at a controlled rate by fluid being imbibed through the wall into the compartment to produce a solution or suspension containing agent, and for imbibition by the means causing it to concentrate the solution or suspension, expand and fill the compartment, whereby agent is released at a rate controlled by the permeability of the wall, the oosmotic pressure gradient across the wall, and the rate of imbibition and expansion of the means over a prolonged period of time.